Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis

Journal of Neuroimmunology

Volumn 215, Issue 1-2, 2009, Pages 125-128

  Vandenbark, Arthur A ^a,b,c   Huan, Jianya ^b,c   Agotsch, Marisa ^c   La Tocha, Dorian ^c   Goelz, Susan ^d   Offner, Halina ^a,b   Lanker, Stefan ^d   Bourdette, Dennis ^a,b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d BIOGEN   (United States)

Author keywords

CD56bright NK cells; Foxp3 expression; IFN 1a; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CD56 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT DURATION;

ADULT; ANTIGENS, CD56; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-BETA; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 70349741303     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.08.007     Document Type: Article

References (20)

1. bright natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5941-5946
2. Bielekova B., Howard T., Packer A.N., Richert N., Blevins G., Ohayon J., Waldmann T.A., McFarland H.F., and Martin R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 66 (2009) 483-489
3. de Andres C., Aristimuno C., delasHeras V., Martinez-Gines M.L., Bartolome M., Arroyo R., Navarro J., Gimenez-Roldan S., Fernandez-Cruz E., and Sanchez-Ramon S. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 182 (2007) 204-211
4. high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35 (2005) 3343-3352
5. Haas J., Fritzsching B., Trubswetter P., Korporal M., Milkova L., Fritz B., Vobis D., Krammer P.H., Suri-Payer E., and Wildemann B. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J. Immunol. 179 (2007) 1322-1330
6. Huan J., Culbertson N., Spencer L., Bartholomew R., Burrows G.G., Chou Y., Bourdette D., Ziegler S.F., Offner H., and Vandenbark A.A. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81 (2005) 45-52
7. Kastrukoff L.F., Lau A., Wee R., Zecchini D., White R., Petkau A.J., Satoh J., and Paty D.W. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J. Neuroimmunol. 145 (2003) 103-114
8. Korporal M., Haas J., Balint B., Fritzsching B., Schwarz A., Moeller S., Fritz B., Suri-Payer E., and Wildemann B. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch. Neurol. 65 (2008) 1434-1439
9. Putheti P., Pettersson A., Soderstrom M., Link H., and Huang Y.M. Circulating CD4 + CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J. Clin. Immunol. 24 (2004) 155-161
10. Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005) 345-352
11. Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 28 (2007) 121-126
12. Segal B.M. The role of natural killer cells in curbing neuroinflammation. J. Neuroimmunol. 191 (2007) 2-7
13. Shevach E.M. Regulatory T cells in autoimmunity. Ann. Rev. Immunol. 18 (2000) 423-449
14. Vandenbark A.A., and Offner H. Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?. Immunology 125 (2008) 1-13
15. Vandenbark A.A., Culbertson N.E., Bartholomew R.M., Huan J., Agotsch M., LaTocha D., Yadav V., Mass M., Whitham R., Lovera J., Milano J., Theofan G., Chou Y.K., Offner H., and Bourdette D.N. Therapeutic vaccination with a trivalent T cell receptor peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 123 (2007) 66-78
16. Venken K., Hellings N., Hensen K., Rummens J.L., Medaer R., D'hooghe M.B., Dubois B., Raus J., and Stinissen P. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4 + CD25+ regulatory T-cell function and FOXP3 expression. J. Neurosci. Res. 83 (2006) 1432-1446
17. Venken K., Hellings N., Thewissen M., Somers V., Hensen K., Rummens J.L., Medaer R., Hupperts R., and Stinissen P. Compromised CD4 + CD25high regulatory T cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3 positive cells and a reduced FOXP3 expression at the single-cell level. Immunology 123 (2007) 79-89
18. low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J. Immunol. 180 (2008) 6411-6420
19. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4 + CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004) 971-979
20. Zhang B., Yamamura T., Kondo T., Fujiwara M., and Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186 (1997) 1677-1687